The realm of weight loss medications has witnessed significant advancements, particularly with the emergence of GLP-1 receptor agonists. Among these, Ozempic and Zepbound have garnered considerable attention. Both are injectable medications capable of inducing long-term weight loss, but with distinct characteristics and FDA approvals. This article aims to provide an informative comparison between Zepbound and Ozempic, exploring their mechanisms, effectiveness, side effects, and other relevant factors to aid in making informed decisions.
Understanding GLP-1 Medications
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone in the body that plays a crucial role in regulating appetite and blood sugar levels. GLP-1 receptor agonists mimic the action of this hormone, offering a multifaceted approach to weight management and glycemic control. These medications work by:
- Slowing down gastric emptying, promoting a feeling of fullness for an extended period.
- Signaling the brain to reduce appetite and cravings.
- Stimulating insulin release from the pancreas, thereby lowering blood sugar levels.
These combined effects make GLP-1 receptor agonists valuable tools in managing type 2 diabetes and achieving significant weight loss, especially when integrated into a comprehensive program that includes nutritional guidance and lifestyle support.
Ozempic: A Semaglutide-Based Medication
Ozempic, containing the active ingredient semaglutide, is an FDA-approved injectable medication administered once weekly. Its primary indication is to improve blood sugar control in adult patients with type 2 diabetes. While not explicitly approved for weight loss, Ozempic's impact on appetite and satiety has led to its widespread off-label use for this purpose. Notably, semaglutide is also marketed under the brand name Wegovy, which holds FDA approval for chronic weight management.
Mechanism of Action
Ozempic and Wegovy both contain semaglutide, a GLP-1 receptor agonist. Semaglutide works by binding to GLP-1 receptors and stimulating insulin release from the pancreas when needed. It also slows down the rate at which food empties from the stomach, leading to a prolonged feeling of fullness and reduced food consumption.
Read also: Understanding Zepbound Insurance
Cardiovascular Benefits
Ozempic and Wegovy are both approved for cardiovascular risk reduction. This means they can reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and type 2 diabetes mellitus (Ozempic) or obesity or overweight (Wegovy).
Dosing and Administration
Ozempic is administered weekly as a subcutaneous injection in the abdomen, thigh, or upper arm. The injection pens deliver doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg. The initial dose is 0.25 mg once weekly, which is then increased to 0.5 mg after four weeks. The maximum recommended dose of Ozempic for blood sugar control is 2 mg weekly. For reducing the risk of kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, the recommended dose is 1 mg weekly after an 8-week titration.
Wegovy is also available as a single-dose pen in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses, administered subcutaneously once weekly. The starting dose is 0.25 mg, which is gradually increased in 4-week intervals until a maintenance dose of 1.7 mg or 2.4 mg is reached.
Zepbound: A Dual-Action Tirzepatide Medication
Zepbound, featuring the active ingredient tirzepatide, is a relatively new injectable medication administered once weekly. It distinguishes itself through a dual-action mechanism, acting as both a GLP-1 receptor agonist and a GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. This dual-action is believed to enhance its effects on appetite suppression and blood sugar regulation. Zepbound received FDA approval for obesity treatment in late 2023. Tirzepatide is also marketed under the brand name Mounjaro, which is FDA-approved for treating type 2 diabetes.
Mechanism of Action
Mounjaro and Zepbound both contain tirzepatide, a dual-acting GIP and GLP-1 receptor agonist. GIP and GLP-1 are both natural incretin hormones. Mounjaro lowers fasting and postprandial (after meals) glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus.
Read also: Weight Loss Drug Coverage by Medicaid
Clinical Studies
Zepbound (tirzepatide) for chronic weight management (weight reduction and maintenance) was studied in 2 randomized, placebo-controlled, 72-week long studies (SURMOUNT-1 and SURMOUNT-2) in over 3,400 adults with obesity or excess weight (overweight) and at least one weight-related condition.
In the Phase 3 SURMONT-1 study, patients taking tirzepatide started at a dose of 2.5 mg once-weekly and then increased the dose by 2.5 mg at four-week intervals to reach their final dose. Weight loss with all three doses as compared to placebo was statistically significant. The percentage of patients with a weight loss of 5% or more was 85% to 91% based on dose, compared to 35% with placebo. People in the study were able to maintain the weight reduction for the full 72-week study period.
In the Phase 3 SURMONT-2 study, patients were randomized to receive Zepbound 10 mg, Zepbound 15 mg, or placebo once weekly. Weight loss with both Zepbound doses as compared to placebo was statistically significant.
Dosing and Administration
Zepbound is available in single-use pens that deliver doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The recommended starting dosage is 2.5 mg subcutaneously once weekly, increasing to 5 mg once weekly after 4 weeks. The recommended maintenance dosages are 5 mg, 10 mg, or 15 mg injected subcutaneously once weekly.
Approvals
In November 2023, Zepbound, the brand name for Eli Lilly's tirzepatide for weight loss, was approved by the FDA. Wegovy received approval in August 2025 for the treatment of adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. Zepbound is approved for use only in adults, while Wegovy is approved for adults and children aged 12 years and older.
Read also: Weight Loss Coverage Details
Comparing Effectiveness for Weight Loss
One of the primary considerations for individuals seeking weight loss medications is their effectiveness. Clinical trial data and meta-analyses suggest that Zepbound may offer a slight advantage in this regard.
- SURMOUNT-5 Clinical Trial: This head-to-head study directly compared tirzepatide (Zepbound) and semaglutide (Wegovy), finding that tirzepatide was superior for weight loss.
- Semaglutide (Wegovy): Participants in clinical trials experienced an average weight loss of approximately 15% of their body weight.
- Tirzepatide (Zepbound): Clinical trials demonstrated that participants on the highest dose of Zepbound achieved an average weight loss of up to 21% of their body weight.
These findings indicate that the dual-action mechanism of tirzepatide may lead to more significant weight loss results for many individuals.
In SURMOUNT-1, at the highest dose (15 mg), people using Zepbound lost an average of 21.8 kg (48 lb) or 21% of their body weight, while at the lowest dose (5 mg), people lost an average of 15.5 kg (34 lb) or 15% of their body weight, compared to 3.2 kg (7 lb), or 3%, on placebo.
In SURMOUNT-2, patients on Zepbound had a 47% greater relative weight loss compared to Wegoy (an average weight reduction of 20.2% with Zepbound compared to 13.7% with Wegovy). People using Zepbound lost on average 50.3 lbs (22.8 kg). Secondary endpoints demonstrated at least a 15% weight loss in 64.6% of those in the Zepbound group compared to 40.1% on Wegovy. In addition, an average waist circumference reduction of 7.2 in (18.4 cm) was seen in the Zepbound group, compared to an average reduction of 5.1 in (13 cm) in the Wegovy group.
Over a 68-week period, adults in the STEP 1 study taking Wegovy lost significantly more weight than those taking an inactive placebo. With Wegovy, an average of 15.9 kg (35 lb), or about 15% of body weight, was seen. In addition, about 84% of people taking Wegovy lost 5% or more of their weight (vs. 31% of people on placebo).
In one 40-week trial, tirzepatide users lost between 16.7 and 24.7 pounds, while semaglutide users at a 1 mg dose lost an average of 12.5 pounds. In another study by Eli Lilly, Zepbound users lost up to 21% of their body weight.
Side Effects
Both Ozempic and Zepbound share a similar side effect profile, with the most common issues being gastrointestinal in nature. These can include nausea, vomiting, diarrhea, constipation, and acid reflux. In clinical trials, the rate of these side effects was comparable between the two drugs, and they are typically mild to moderate in severity, tending to subside as the body adjusts to the medication.
Incretin mimetics may cause nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion (dyspepsia), and stomach (abdominal) pain.
The labeling of these medicines carry a Boxed Warning for possible thyroid tumors, including cancer, which has been seen in animal studies.
After these medicines were approved by the FDA, ileus was reported as a possible side effect and updated in the product labels. An ileus (paralytic ileus) is an intestinal blockage that results in the failure of the intestinal contents to pass through the gut, but it doesn't involve a physical blockage.
There have also been concerns about the use of incretin mimetics (GLP-1 type medications) in patients undergoing general anesthesia because these medications can lead to a delay in stomach (gastric) emptying. The American Society of Anesthesiologists suggests that adults and children on these types of GLP-1 medicines stop taking it prior to surgery.
Cost and Insurance Coverage
The financial aspect of these medications is a significant consideration. Both Ozempic and Zepbound are relatively expensive, with a month's supply potentially exceeding $1,000 without insurance coverage. Insurance coverage often plays a crucial role in determining accessibility.
- Coverage for Diabetes: Insurance plans are more likely to cover these medications when prescribed for their FDA-approved use in treating type 2 diabetes (Ozempic/Mounjaro).
- Coverage for Obesity: Coverage for weight loss (Wegovy/Zepbound) varies widely among insurance plans. Many plans may not cover these medications for obesity or may require prior authorizations and documentation of previous unsuccessful weight loss attempts.
Compounded Semaglutide and Tirzepatide
Due to the high cost and occasional supply shortages of brand-name drugs, some patients turn to compounded versions of semaglutide and tirzepatide. Compounding pharmacies can create customized versions of the active ingredients at a lower cost. However, it is essential to be aware that compounded drugs are not subject to the same strict oversight and regulations as FDA-approved medications.
Achieving and Maintaining Weight Loss
These medications can significantly aid in weight loss by controlling hunger and cravings, making it easier to establish healthy habits. However, maintaining long-term weight loss requires a commitment to lifestyle changes, including:
- A focus on protein intake.
- Planned meals.
- Regular exercise.
- Restricted carbohydrate intake.
Medical supervision is crucial for safe and healthy weight loss, with a supervised program that includes monitoring, nutritional guidance, and behavioral counseling leading to better outcomes and the establishment of habits necessary for maintaining weight loss.